O122

Dual therapy with a boosted protease inhibitor plus lamivudine is an effective maintenance strategy in patients on second-line antiretroviral therapy in Africa: the ANRS 12286/MOBIDIP trial

Laura Ciaffi1; Sinata Koulla-Shiro2; Adrien Sawadogo3; N Fatou Ngom Gueye2; Vincent Le Moing4; Sabrina Eymard-Duvernay3; Suzanne Izard3; Jacques Zoungrana2; Pretty Mbouyap2; Mamadou Diallo2; Guillaume Bad0; Koumba Toure Kane5; Avelin Aghokeng3; Martine Peeters7; Jacques Reynes9 and Eric Delaporte7

1IRD INSERM, UMI 233, Montpellier, France. 2Faculty of Medicine and Biomedical Sciences, University of Yaounde 1, Yaounde, Cameroon. 3Hôpital de Jour, Centre Hospitalier Universitaire de Souro Sanou, Bobo Dioulasso, Burkina Faso. 4Hôpital de Jour, Centre Hospitalier Universitaire de Fann, Dakar, Senegal. 5Projet MOBIDIP, Agence Nationale de Recherche sur le SIDA et les hépatites virales (Cameroun Site), Yaounde, Cameroon. 6Centre Hospitalier Universitaire de Fann, CRDF, Dakar, Senegal. 7Laboratoire de Bactériologie-Virologie, Centre Hospitalier Universitaire Aristide Le Dantec, Dakar, Senegal. 8Virology laboratory IMPM-IRD, Centre de Recherche sur les Maladies Emergentes et, Yaounde, Cameroon. 9Maladies Infecctueuses, Centre Hospitalier Universitaire Montpellier, Montpellier, France

Introduction: Second-line ART regimens with ritonavir-boosted protease inhibitor (PI/r) plus nucleoside reverse transcriptase inhibitors (NRTIs) have shown good efficacy in resource-limited settings [1–3]. But issues of costs, toxicity and future options make a simplified maintenance treatment a strategy of interest. We aimed to compare two maintenance treatments with PI/r in mono- or dual therapy (plus lamivudine (3TC)) in a group of virally suppressed patients on second-line ART.

Material and methods: A randomized, open-label, multicentre clinical trial was conducted in Cameroon, Senegal and Burkina Faso. HIV-1 positive patients followed in the ANRS 12186 2LADY trial [3] on stable PI plus NRTIs second-line ART with HIV-1 RNA viral load (VL) below 200 copies/mL, CD4 above 100 cells/mm³ and adherence ≥90%, were included in a two arms trial comparing monotherapy with the ongoing PI/r: darunavir (DRV)/r or lopinavir (LPV)/r – mono arm – with the same PI/r associated with 3TC 300 mg – dual arm. The primary outcome was failure rate at 96 weeks. Treatment failure was defined as 1) a confirmed VL above 500 copies/mL, 2) reintroduction of the NRTI backbone or 3) the interruption of PI.

Results: From March 2014 to January 2015, 265 patients were! randomized (133 in mono arm and 132 in dual arm). Included patients were mainly women (73%), with a median age of 42 years [interquartile range (IQR) 36–50]; median CD4 was 475 cells/mm³ (IQR 379–652) and median time on second line was 37 months (IQR 30–47). At the failure of first line, 96% had the M184V mutation. For the Data Safety Board meeting in March 2016, 48 data were analyzed. The Board advised for the interruption of the mono arm. In the ITT analysis, 3.0% (95% CI 0.8–7.6) and 22.6% (95% CI 15.8–30.6) of patients failed in the dual and mono arm respectively (p < 0.001). Median time to failure was 24 weeks. All failing patients, except one, resuppressed to less than 200 copies/mL in a median time of 12 weeks after reintroduction of the NRTI backbone. Increase in CD4 was significantly higher in the dual arm (48 vs. 7 cells/mm³). No differences in adverse events were observed. Neither adherence, nor nadir CD4 count, nor PI drug were associated with failure.

Conclusions: After viral suppression with PI plus NRTIs in second-line therapy, maintenance with PI/r plus 3TC is associated with a high rate of success despite the presence of M184V while PI/r mono-therapy cannot be recommended.

References

O123

Resistance profile analysis of treatment-experienced HIV-1 infected patients switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) plus darunavir (DRV)

Nicolas Margot1; Renee Ram2; Moupali Das3; Marshall Fordyce2; Scott McCallister2; Michael Miller2 and Christian Callebaut1

1Clinical Virology, Gilead, Foster City, CA, USA. 2Clinical Research, Gilead, Foster City, CA, USA

Introduction: In study GS-US-292-0119, virologically suppressed, treatment-experienced patients on complex multi-tablet regimens [1] were switched to a simpler, more convenient antiretroviral regimen. After 48 weeks, viral suppression was maintained in 94.4% of patients who switched to E/C/F/TAF + DRV compared to 76.1% in the DRV-containing "Stay on Baseline Regimen" arm. All patients had documented resistance to >2 classes of antiretroviral (ARV) agents at baseline. Detailed ARV regimens and the resistance profile of the study population are described.

Methods: Historical genotypic reports were analyzed for resistance-associated mutations (RAMs) to ARVs. The Stanford HIVdb algorithm version 8.01 was used to calculate genotypic susceptibility scores (GSS). For each drug, a 5-point scale was used: susceptible, potential low-level resistance, low-level resistance, intermediate-level resistance and high-level resistance were scored as 1, 0.75, 0.5, 0.25 and 0, respectively. The total GSS for a given regimen was calculated as the sum of the scores for each individual drug.

Results: A total of 94.8% had documented resistance to >2 classes of ARVs, including protease inhibitors (Pis; 34.8%), non-nucleoside RT inhibitors (NNRTIs; 88.1%) and NRTIs (94.8%). The most common PI-RAMs were L90M (15.6%) and V82I (40.4%), while 36.3% had documented resistance to 3TC. The most common NNRTI-RAMs were M184V/I (83%) and K65R (80.5%). The most common PI-RAMs were L90M (15.6%) and V82I (40.4%), while 36.3% had documented resistance to 3TC. The most common NNRTI-RAMs were M184V/I (83%) and K65R (80.5%). The most common RT-RAMs were T215Y/F (45.2%) and D67N (40.8%). The most common NNRTI-RAMs were M184V/I (83%) and K65R (80.5%). The most common RT-RAMs were T215Y/F (45.2%) and D67N (40.8%).

The distribution of GSS at study entry was similar across all switching arms. In the DRV-containing "Stay on Baseline Regimen" arm, 11/89 patients (12.4%) had GSS >7.6, and 27/89 patients (30.3%) had GSS ≥9. The frequency of GSS was similar across all switching arms. In the DRV-containing "Stay on Baseline Regimen" arm, 11/89 patients (12.4%) had GSS >7.6, and 27/89 patients (30.3%) had GSS ≥9.